Buy HIMS Stock At $56?

Hims & Hers (HIMS) stock recently surged 42% to $59, primarily driven by a U.S. federal judge's dismissal of Eli Lilly's lawsuit against rival telehealth firm Willow Health regarding compounded GLP-1 medications. This development significantly alleviated investor concerns about HIMS's own legal and regulatory risks surrounding its compounded GLP-1 offerings. While the company demonstrates strong operational performance and financial stability, its current $13 billion market capitalization and valuation are now considered high following this substantial rally.

Analysis

Hims & Hers (HIMS) stock experienced a significant 42% rally over the past month, a move primarily catalyzed by a U.S. federal judge's dismissal of a lawsuit Eli Lilly had filed against a rival telehealth company over compounded GLP-1 drugs. This legal development materially reduced investor concerns regarding Hims & Hers' own litigation and regulatory risks tied to its compounded GLP-1 offerings, which had been a major overhang on the stock. Fundamentally, the company exhibits exceptionally strong top-line growth, with last-twelve-month (LTM) revenues increasing 89% to $2.0 billion and the most recent quarterly revenue growing 72.6% year-over-year. This growth is supported by a very strong balance sheet, evidenced by a low 7.9% Debt-to-Equity ratio and a high 61.0% Cash-to-Assets ratio. However, this operational strength is contrasted by weak profitability metrics, including an LTM operating margin of just 6.2%. Following the recent price surge, the stock's valuation at a $13 billion market cap is now considered high, presenting a key conflict for investors weighing the de-risked legal profile and strong growth against a stretched valuation and modest margins.

Key Decisions for Investors

• Given the stock's rapid 42% appreciation and resulting high valuation, investors with existing positions could consider trimming their holdings to realize partial gains while maintaining exposure to the company's strong growth trajectory.
• Potential new investors should be cautious of initiating a position at these elevated levels, as the current price largely reflects the recent positive legal news and presents significant valuation risk without a pullback.
• Future investment decisions should be contingent on the company demonstrating a clear path to improved profitability; specifically, monitor whether operating margins can expand beyond the current 6.2% to justify its growth-oriented valuation.
• Investors must continue to track any developments related to the specific class-action complaints and regulatory scrutiny that Hims & Hers itself faces, as the positive legal signal from the separate Eli Lilly case does not fully eliminate company-specific risks.